{
  "disease": "breast cancer",
  "date_generated": "2026-02-14",
  "drugs_investigated": [
    "DOXORUBICIN",
    "TAMOXIFEN",
    "PACLITAXEL",
    "FULVESTRANT"
  ],
  "note": "These are FDA-approved breast cancer drugs. Trial terminations reflect portfolio management, not repurposing opportunities.",
  "results": {
    "DOXORUBICIN": {
      "total_failed_trials": 15,
      "classification": "MIXED",
      "repurposing_viable": false,
      "safety_flags": 1,
      "business_dropouts": 4,
      "trials": [
        {
          "nct_id": "NCT02131506",
          "title": "A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer",
          "status": "TERMINATED",
          "why_stopped": "Safety reasons",
          "failure_category": "SAFETY",
          "phases": ["PHASE1"],
          "conditions": ["HER-2 Positive Breast Cancer"]
        },
        {
          "nct_id": "NCT00542191",
          "title": "Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer",
          "status": "TERMINATED",
          "why_stopped": "Enrollment Completed",
          "failure_category": "BUSINESS/LOGISTICS",
          "phases": ["PHASE2"],
          "conditions": ["Breast Cancer"]
        },
        {
          "nct_id": "NCT00082095",
          "title": "To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older",
          "status": "TERMINATED",
          "why_stopped": "The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in 20 months)",
          "failure_category": "BUSINESS/LOGISTICS",
          "phases": ["PHASE3"],
          "conditions": ["Metastatic Breast Cancer"]
        }
      ],
      "interpretation": "Already approved for breast cancer. 15 terminated trials mostly due to accrual issues (business/logistics). 1 safety-related termination in a combination study (lapatinib + Caelyx). Not a repurposing candidate."
    },
    "TAMOXIFEN": {
      "total_failed_trials": 15,
      "classification": "MIXED",
      "repurposing_viable": false,
      "safety_flags": 1,
      "business_dropouts": 2,
      "trials": [
        {
          "nct_id": "NCT05128773",
          "title": "Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer",
          "status": "TERMINATED",
          "why_stopped": "Sponsor decision to prematurely stop the study, not linked to any safety concern",
          "failure_category": "SAFETY",
          "phases": ["PHASE3"],
          "conditions": ["Breast Cancer"]
        },
        {
          "nct_id": "NCT02395627",
          "title": "Reversing Therapy Resistance With Epigenetic-Immune Modification",
          "status": "TERMINATED",
          "why_stopped": "Insufficient efficacy in an unselected patient population",
          "failure_category": "EFFICACY",
          "phases": ["PHASE2"],
          "conditions": ["Breast Neoplasms"]
        }
      ],
      "interpretation": "Standard of care for ER+ breast cancer. Terminated trials mostly reflect slow accrual or combination study failures, not tamoxifen itself. Not a repurposing candidate."
    },
    "PACLITAXEL": {
      "total_failed_trials": 15,
      "classification": "BUSINESS/LOGISTICS",
      "repurposing_viable": true,
      "safety_flags": 0,
      "business_dropouts": 4,
      "trials": [
        {
          "nct_id": "NCT00542191",
          "title": "Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer",
          "status": "TERMINATED",
          "why_stopped": "Enrollment Completed",
          "failure_category": "BUSINESS/LOGISTICS",
          "phases": ["PHASE2"],
          "conditions": ["Breast Cancer"]
        },
        {
          "nct_id": "NCT00251095",
          "title": "Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer",
          "status": "TERMINATED",
          "why_stopped": "Failed primary endpoint",
          "failure_category": "EFFICACY",
          "phases": ["PHASE3"],
          "conditions": ["Breast Neoplasm"]
        },
        {
          "nct_id": "NCT04251169",
          "title": "Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression",
          "status": "TERMINATED",
          "why_stopped": "The enrollment was stopped prematurely due to the lack of funding",
          "failure_category": "BUSINESS/LOGISTICS",
          "phases": ["PHASE2"],
          "conditions": ["Metastatic Breast Cancer"]
        }
      ],
      "interpretation": "Standard chemotherapy for breast cancer. 15 terminated trials with NO safety flags. Mostly accrual issues and combination study portfolio decisions. Already in clinical use - not a repurposing candidate."
    },
    "FULVESTRANT": {
      "total_failed_trials": 15,
      "classification": "BUSINESS/LOGISTICS",
      "repurposing_viable": false,
      "safety_flags": 1,
      "business_dropouts": 6,
      "trials": [
        {
          "nct_id": "NCT00774878",
          "title": "Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (FaslodexÂ®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer",
          "status": "TERMINATED",
          "why_stopped": "Company decision to discontinue the AVE1642 development program, not due to any safety or efficacy concerns",
          "failure_category": "SAFETY",
          "phases": ["PHASE2"],
          "conditions": ["Breast Neoplasms"]
        },
        {
          "nct_id": "NCT00543127",
          "title": "Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole",
          "status": "TERMINATED",
          "why_stopped": "Unjustified decision of company that funded the trial.",
          "failure_category": "BUSINESS/LOGISTICS",
          "phases": ["PHASE3"],
          "conditions": ["Breast Cancer"]
        }
      ],
      "interpretation": "Approved for ER+ breast cancer. 6 business-related terminations mostly due to accrual or portfolio decisions. 1 safety termination was due to discontinuation of the combination partner (AVE1642), not fulvestrant. Not a repurposing candidate."
    }
  },
  "summary": {
    "key_finding": "All four drugs investigated (DOXORUBICIN, TAMOXIFEN, PACLITAXEL, FULVESTRANT) are already FDA-approved for breast cancer treatment. Their terminated trials reflect normal clinical development portfolio management, not repurposing opportunities.",
    "repurposing_insight": "For true repurposing candidates in breast cancer, investigate drugs with INVERSE FAERS signals that are NOT currently approved for breast cancer (e.g., TEMOZOLOMIDE, DASATINIB, ETOPOSIDE)."
  }
}
